Companies / Simmunome
AI disease simulation platform for drug target validation and patient biomarkers.
simmunome.com| Round | Date | Amount | Investors |
|---|---|---|---|
| Pre-seed | Sep 18, 2023 | C$2M | Theodorus (lead); Investissement Québec (Eurêka Fund), BKR Capital, Sandpiper Ventures, ACET Capital. C$2M all-equity pre-seed closed early September 2023, announced Sep 18; led by Theodorus Investment Funds with Fonds d'investissement Eurêka (Investissement Québec), BKR Capital, Sandpiper Ventures and ACET Capital |
Data as of September 26, 2026. Suggest a correction